Excerpt: Tina Banerjee, a healthcare analyst contributing to the Smartkarma platform, described the deal as a “big positive and much needed for Daiichi Sankyo.” The agreement has raised expectations for Daiichi’s oncology drug pipeline and generated a renewed …
geneonline.com • (Opens in a new window) ⧉
Are you a Professional Journalist?
The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.
